Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 6/20 | 0.45 |
| ▸ | CNR1 | P21554 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.38 |
| ▸ | SRC | P12931 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.36 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL215944 | 0.83 | CNR2 (0.63) | L3MBTL1CNR2CNR1KDM4EGAA | |
| SCHEMBL29956399 | 0.83 | L3MBTL1 (0.61) | L3MBTL1KDM4EGAAHPGDHSD17B10 | |
| SCHEMBL2746512 | 0.79 | NOTUM (0.61) | CNR2CNR1KDM4EGAAHSD17B10 | |
| SCHEMBL217825 | 0.76 | CNR2 (0.78) | CNR2CNR1KDM4EGAAHPGD | |
| SCHEMBL4957913 | 0.76 | GPR35 (0.50) | L3MBTL1CNR2KDM4EHPGDHSD17B10 | |
| SCHEMBL2736526 | 0.76 | KDM4E (0.44) | CNR2CNR1KDM4EGAAHPGD | |
| SCHEMBL11231545 | 0.75 | MEN1 (0.46) | L3MBTL1CNR2CNR1MEN1KMT2A | |
| SCHEMBL3336907 | 0.73 | KDM4E (0.42) | KDM4EGAAHPGDHSD17B10NOTUM | |
| SCHEMBL2745654 | 0.71 | CNR2 (0.65) | L3MBTL1CNR2CNR1KDM4EGAA | |
| SCHEMBL16627568 | 0.71 | CA12 (0.51) | L3MBTL1CNR2CNR1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088924-B2 | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor | SHIONOGI & CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-8088924-B2 | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor | SHIONOGI & CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20100081686-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter | TADA YUKIO | 2010-04-01 | — | — | US | disclosed |
| US-20100081686-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter | TADA YUKIO | 2010-04-01 | — | — | US | disclosed |
| US-7652141-B2 | Immunosuppressants, analgesics, antiinflammatory agents | SHIONOGI & CO., LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| US-7652141-B2 | Immunosuppressants, analgesics, antiinflammatory agents | SHIONOGI & CO., LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| CN-100575345-C | 2 type Cannabined receptors are had in conjunction with active Pyridione derivatives | SHIONOGI & CO | 2009-12-30 | — | — | CN | disclosed |
| EP-2130820-A1 | Antipruritics | SHIONOGI & CO., LTD. (JP) | 2009-12-09 | — | — | EP | disclosed |
| EP-1477186-B1 | ANTIPRURITICS | SHIONOGI & CO (JP) | 2009-11-11 | — | — | EP | disclosed |
| EP-1357111-B1 | 2-PYRIDONE DERIVATIVES HAVING AFFINITY FOR CANNABINOID TYPE 2 RECEPTOR | SHIONOGI & CO (JP) | 2009-08-05 | — | — | EP | disclosed |
| US-20080312292-A1 | Antipruritics | YASUI KIYOSHI | 2008-12-18 | — | — | US | disclosed |
| US-20080312292-A1 | Antipruritics | YASUI KIYOSHI | 2008-12-18 | — | — | US | disclosed |
| US-20060052411-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor | TADA YUKIO | 2006-03-09 | — | — | US | disclosed |
| US-6977266-B2 | Pyridone derivatives having affinity for cannabinoid 2-type receptor | SHIONOGI & CO., LTD. (JP) | 2005-12-20 | — | — | US | disclosed |
| US-20050101590-A1 | Cannabinoid receptor agonists | SHIONOGI & CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1477186-A1 | ANTIPRURITICS | SHIONOGI & CO., LTD. (JP) | 2004-11-17 | — | — | EP | disclosed |
| US-20040082619-A1 | Pyridone derivatives having affinity for cannabinoid 2-type receptor | SHIONOGI & CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| CN-1492856-A | Pyridone derivative having affinity for cannabinoid 2-type receptor | ��Ұ����ҩ��ʽ���� | 2004-04-28 | — | — | CN | disclosed |
| EP-1357111-A1 | PYRIDONE DERIVATIVE HAVING AFFINITY FOR CANNABINOID 2-TYPE RECEPTOR | SHIONOGI & CO., LTD. (JP) | 2003-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081686-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter | CNR2, CNR1, NPY2R | L3MBTL1 4225/4885CNR2 1/4885CNR1 2/4885 |
| US-20050101590-A1 | Cannabinoid receptor agonists | CNR1, CNR2, OPRL1 | L3MBTL1 3887/4885CNR2 2/4885CNR1 1/4885 |
| US-20060052411-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor | CNR2, CNR1, NPY2R | L3MBTL1 3979/4885CNR2 1/4885CNR1 2/4885 |
| US-20080312292-A1 | Antipruritics | CNR1, CNR2, OPRL1 | L3MBTL1 3630/4885CNR2 2/4885CNR1 1/4885 |
| US-20040082619-A1 | Pyridone derivatives having affinity for cannabinoid 2-type receptor | CNR1, CNR2, NPY1R | L3MBTL1 3450/4885CNR2 2/4885CNR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.